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Abstract
Certain non-coding DNA sequences in the eukaryotic genome regulate gene expression.
These non-coding regulatory regions, including promoters and enhancers, are controlled by the
binding of multiple transcription factors which act together to regulate gene transcription. The
number of potential transcription factor combinations regulating any gene presents a massive
experimental challenge. One well-known transcription factor, p53, activates multiple
transcription pathways involved in tumor suppression, primarily through engagement with
enhancers. p53 is one member of a paralogous transcription factor family, which includes the
factor p63. Whereas p53 is involved in tumor suppression, p63 is a transcription factor
responsible for maintaining epithelial cell populations through its ability to bind to and regulate
enhancers. p63 and p53 are often bound to the same enhancers in the genome, suggesting a more
complex regulation than predicted by their canonical functions. We therefore aimed to better
understand how genomic binding sequences and other factors regulate p53 and p63 activity at
enhancers. Luciferase reporter gene assays were utilized to measure the transcriptional output of
various p63 and p53 enhancers after genetically altering flanking DNA sequence motifs. We
found that changing these flanking regions revealed core regulatory sequences that drive p53 and
p63 transcriptional activity. We also determined that p63-bound enhancers, but not those bound
by p53, had context-dependent activity. Depending on the cell type, these enhancers are active or
inactive, with basal expression of p63 determining their activity. Our data provide new insight
into the regulation of p53 family enhancers, and further work will lead to a better understanding
of transcription factor activity and function at enhancers.
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Introduction
Genes are sequences of DNA which can vary from a few hundred to more than 2 million
base pairs in length (Biscotnini, 2019). The information within genes can be decoded by a
process called transcription, whereby the DNA information is transcribed into a new molecule
called mRNA (messenger RNA). The information on an mRNA is then decoded by ribosomes to
produce a polypeptide. Gene transcription is tightly controlled by gene regulatory networks to
ensure the correct spatial and temporal expression of the gene. This regulation occurs through
regulatory elements, which include enhancers and promoters. Promoters are DNA sequences
upstream of a target gene, where transcription factors and RNA polymerase bind to a
transcription start site in order to initiate transcription. While promoters are strictly required for
transcription, enhancers are not required for basal transcription. However, enhancers control the
abundance and frequency of transcription, as well as the spatial and temporal expression of genes
in the larger organism. Both regulatory elements function through the combinatorial binding of
transcription factors, which direct and regulate the general transcription machinery. The
expression of different sets of genes in different tissues and at different times is known as
differential gene expression. This requires the coordinated effort of multiple transcription factors,
which then binds to different combinations of enhancers and promoters.
Enhancers are unique, non-coding sections of the eukaryotic genome that regulate
transcription by recruiting transcription factors. Enhancers are a few hundred base pairs in
length, and they can be located at various distances from the target gene, up to a mega base
away. However, transcription factors rarely act alone at enhancers. The binding of the correct
combination and orientation of factors to both the enhancer and promoter regions initiates
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transcription of the gene. Their activity should therefore be studied in combination with other
transcription factors (Spitz & Furlong, 2012).
The p53 family of transcription factors includes p53, p63, and p73, and is highly enriched
at enhancer regions. These proteins can bind to the same DNA sites, have similar DNA binding
domains, and can activate some of the same target genes. However, there is evidence that they
are not identical nor redundant, as previous studies have demonstrated that the loss of one family
member during embryonic mouse development results in severe deformations, if not lethality
(Nostrand et al., 2017). While p53 has a major role in tumor suppression, p63 is responsible for
epithelial morphogenesis, and p73 is known to maintain neuronal structures. We are primarily
focused on the activities and functions of p53 and p63. p53 is a transcription factor that is
expressed in every cell type. It acts a trans-activator, which enhances the transcription of p53
target genes by recruiting histone-modifiers (Brady & Attardi, 2010). Furthermore, p53 is
mutated in 50% of cancers due to its crucial role in the regulation of downstream genes
responsible for cell cycle arrest, senescence, autophagy, and apoptosis (Zilfou & Lowe, 2009).
While p63 shares some of the same target genes with p53, p63 primarily regulates
downstream targets that drive the early development of epidermal structures and their functions
(Koster, 2010). Loss of both proteins is known to compromise cell senescence and apoptosis,
leading to many different cancers and diseases. Previous studies have shown that p63-knockout
mice develop with truncated limbs, the absence of a stratified epidermis, and deformations of
other appendages (Romano et al., 2012). The literature also suggests that p63 can and does
interact with the p53 network. However, it is unknown what defines a p63 enhancer, what the
role of p63 is at enhancers, and what the target genes of p63-dependent enhancers are.
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A previous experiment in our lab screened hundreds of p53 and p63 enhancers including
a single group which all bind p63, but do not bind p53. We found this interesting because both
proteins bind a highly similar DNA response element and often bind the same regions. However,
this group of p63 enhancers showed minimal activity in a massively parallel reporter assay
(MPRA) when the p63 protein was present and did not respond to p53 induction. Loss of p63 or
p63 binding site led to decreased enhancer activity. This study also shows that the loss of p53
and/or p63 had detrimental effects on p53/p63 bound enhancers but positive effects on p53/p63
independent enhancers. We wanted to identify the gene associated with these seemingly p63
bound but lowly active enhancers in vivo. We hope to dissect these regions and to understand the
interplay between p53 and p63 using these locations. In order to further investigate these results,
we chose a number of enhancers from this p63-only group. Luciferase assays were performed
using two different cell lines in order to study the effect of the presence and absence of p63 in
the native cell environment on enhancer activity. The enhancers were chosen based on their
location to genes that were downregulated in p63 knockdown cell lines, their enrichment of p63
protein, and the presence of active enhancer chromatin marks.
To study the activity of these enhancers, dCas9-KRAB was targeted to the p63 binding
sites of each of the enhancers. RNA sequencing was utilized to measure the output of these ten
blocked enhancers to determine their enhancer functions. Further experiments can then be done
to identify the core regulatory sequences that determine the activity of these enhancers.
Ultimately, better knowledge of how p53 and p63 enhancers function under stress conditions will
lead to a better understanding of their full impact on gene expression.
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Materials and Methods
I. Cloning cluster 2 enhancers for Luciferase assays
1. Construction of reporter plasmid
The three enhancers were first given a numeric code: E231 for CUX1, E245 for CTSV,
and E220 for DTHD1. Primers were designed using IDT PrimerQuest Tool to amplify enhancer
regions from human genomic DNA. SnapGene and an online primer design tool (NEBuilder)
were used to generate primers for Gibson assembly into pGL4.24, and were purchased from IDT.
The enhancer sizes were verified by running them on a 2% agarose gel with a 100bp ladder. The
three bands containing the different enhancer sequences were then cut from the gel for DNA
extraction and purification.
Additionally, the pGL4.24 plasmid was restriction digested using the HindIII and KpnI
restriction enzyme sites. The size of the cut plasmid was then verified by running a 1% agarose
gel with a 1000bp ladder. The band was excised from the gel and purified using the NEB
Monarch Gel Extraction kit. Finally, Gibson assembly was used to ligate each enhancer to a
pGL4.24 plasmid at the HindIII and KpnI sites using the NEB HiFi Genome Assembly kit.
Ligation products were selected after transformation and growth on LB-Ampicillin plates, and
DNA sequencing was performed to verify the correct sequence and orientation of the ligated
plasmid.

2. Bacterial transformation
The reporter assay plasmids were transformed into chemically-competent bacterial cells
(stbl3 from New England BioLabs) and then plated onto LB-Ampicillin plates. One colony per
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enhancer was picked and grown overnight in 5mL of liquid culture at 37˚C in shaking culture.
Plasmid DNA was then isolated using standard silica column and alkaline lysis methodologies.

3. Luciferase assays of cluster 2 enhancers in HCT116 and MCF10a cells
HCT116 WT, HCT116 Np63, MCF10a WT, and MCF10a p63KD cells were seeded at
150,000 cells into 6-well dishes. The cell lines were then transfected with either one of the
cluster 2 enhancers (E220, E231, E245), a no-enhancer negative control, or an ATF3 positive
control using JetPrime transfection reagent. Dual Luciferase assays (Promega Dual-Glo) were
then performed on each of the cell lines in three technical and three biological replicates as per
manufacturer’s standard recommendations.

II. Cloning cluster 2 enhancers for in vivo analysis of p63 dependent enhancer activity
1. Construction of reporter plasmid
The ten randomly selected Cluster 2 enhancers were first given a numeric code: 197, 198,
200, 206, 213, 236, 254, 258, 275, 288 in order to blind us to their identity during future
experiments. One to two guide RNAs per enhancer were designed using the MIT CRISPR
Design (reference) tool to target each of the enhancer sequences and were purchased from IDT
(Integrated DNA Technologies). Additionally, the parental KRAB plasmid (Addgene plasmid
#110820, dCas9-KRAB was a gift from Alejandro Chavez & George Church) was restriction
digested using the Esp31 (BsmBI) restriction enzyme sites and then 5’ phosphates were removed
using shrimp alkaline phosphatase (SAP). Primer pairs were phosphorylated at the 5’ end using
T4 PNK and ATP at 37˚C for 30 minutes. Phosphorylated primers were then annealed by mixing
equimolar amounts (10mM) in water, heating to 95˚C, followed by controlled cooling to 25˚C (at
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a rate of 1˚C/minute) in a thermocycler. Annealed primers were diluted to 10uM and used in a
ligation reaction with dephosphorylated backbone and T4 DNA ligase.

2. Bacterial transformation
Ligation products were transformed into New England BioLabs stbl3 E.coli cells and
then plated onto LB-Ampicillin plates for selection of correctly ligated products. Plasmids were
isolated from bacterial transformations and sent for Sanger sequencing to test for proper ligation
products.

3. Viral transduction
HEK293FT cells were seeded at 900,000 cells per well of a 6-well dish. The cell lines
were then transfected with sequence-verified lentiviral-dCas9-KRAB-gRNA constructs targeting
either one of the 10 test enhancers, a known enhancer positive control (GDF15), or the negative
control (FGF2 enhancer, inactive in MCF10A cells). The viral media was collected after 24
hours and again after 48 hours, filtered, and 8g/L of polybrene was added to increase
transduction efficiency. MCF10A cells were seeded at 150,000 cells into 6-well dishes. The cell
lines were then transduced with 1mL each of the twelve viral preparations, along with a negative
control containing no virus. Cells were selected 48 hours post-transduction with 2g/mL
Puromycin for 24 hours. Cells surviving selection were cryopreserved or used directly in
experiments.
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4. RNA-seq analysis
Total RNA was extracted and purified from virally-transduced cell lines using the EZNA
Total RNA Kit (Omega BioTek). An RNA-seq library was made using the BioO NEXTflex
Rapid Directional RNA-Seq method. To summarize, 1ug of total RNA was used as the starting
point for polyA-RNA selection using poly-dT-coupled magnetic beads. The resulting polyARNA was fragmented to an average size of 250bp. These fragments were then used for randomly
primed 1st strand synthesis, followed by 2nd strand synthesis using RNAseH-mediated nicking
and substitution of dTTP with dUTP. This allows for downstream detection of the original
strand, thus allowing quantification of strandedness. Sequencing adapters and PCR were then
performed to add both required sequencer information and unique barcode sequences. The
quality of the resulting library was confirmed using a Qubit fluorimeter, qPCR (using the BioRad
iTaq Universal SYBR Green One-Step Kit), and with capillary electrophoresis (Agilent
Bioanalyzer at the University at Albany Cancer Research Center). All 12 libraries were pooled at
an equal molar amount and a 1x75bp sequencing run was performed using a NextSeq 500
instrument. Transcript abundance was determined using salmon (reference) against the hg19
RefSeq genome assembly.

5. MIR205 CRISPR-KRAB-dCas9 qPCR
MCF10a WT cells were seeded at ??? cells into a 6-well dish. The cell lines were then
transfected with either E197, the positive control (GDF15), or no virus. The cells were then
selected 48 hours post-transduction with 2g/mL Puromycin for 24 hours. Transduced cells were
lysed and the total RNA was extracted and purified using the ENZA Total RNA Kit. qPCR was
then performed on cDNA generated from total extracted RNA.
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Results
We began by randomly selecting three enhancer sequences from the previously
performed MPRA experiment. The three p63 enhancer sequences (E245, E231, E220) were first
amplified out of genomic DNA utilizing PCR. The primers were designed to encompass what we
believed represented the entire enhancer sequence, using DNAseI-hypersensitivity data from the
ENCODE Project (Thurman et al., 2012). The primers were designed to have 5’ homology to
the enhancer test vector pGL4.24 in order to allow for downstream Gibson cloning. The
enhancer sizes ranged from 265 to 530bp after considering the entirety of the DNAseIhypersensitive region, as confirmed by 2% agarose gel analysis with a 100bp ladder. The three
enhancer sequences amplified out of genomic DNA match with their expected amplicon sizes
based on their primer sequences (Fig.1). The bands containing the different enhancer sequences
were then cut from the gel for DNA extraction and purification and the resulting concentrations
were measured with the Qubit High Sensitivity dsDNA kit and the Qubit fluorimeter.
Additionally, the pGL4.24 plasmid was restriction digested using the HindIII and KpnI
restriction enzymes. This plasmid serves as the backbone and contains a minimal RNA
polymerase II promoter driving expression of the firefly luciferase gene. The correct size of the
digested plasmid (4300bp) was then verified by running a 1% agarose gel with a 100bp ladder
(Fig.2.) This band was then cut from the gel for DNA extraction and purification. Finally,
Gibson Assembly was used to ligate each enhancer to the restriction digested and purified
pGL4.24 plasmid at the HindIII and KpnI sites. After selection of ampicillin-resistant colonies,
plasmid DNA was extracted and sequenced to verify the correct sequence and orientation of
insertion.
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Once these plasmids were sequence-verified, they were then re-transformed into sbl3
competent E.coli cells in order to generate more copies of the plasmids containing one of the
three enhancer sequences. Finally, a midi-prep process was used to extract pure, supercoiled and
endotoxin-free DNA from bacterial cells. These plasmids are used in further experiments with
mammalian epithelial cells (MCF10a cells) and human colorectal cancer cells (HCT116 cells)
expressing the two isoforms of p63 to verify that they perform enhancer functions.
A set of Luciferase assays were performed on two cell types: MCF10a (derived from
normal human breast epithelial cells) and HCT116 (derived from human colon cancer cells).
MCF10A cells natively express p63 while HCT116 cells do not. These experiments aimed to test
the ability of p63 to activate enhancers and whether p63 would be sufficient for this activity. In
order to do this, we created two cell models. First, we created an MCF10A cell line with reduced
expression of p63, called MCF10a p63KD. A short hairpin RNA (shRNA) was designed against
the p63 DNA binding domain, which is predicted to target all p63 mRNA transcripts. This was
restriction cloned into a lentiviral vector backbone downstream of an RNA polymerase IIIpromoter. This vector also contained a selectable marke for puromycin resistance. A control
shRNA was produced that targets an Arabadopsis-specific mRNA, such that it would not
actually affect RNA stability in human cell lines. Virus was produced as described in Materials
and Methods, and infected cells were selected using puromycin.
We then created a version of the HCT116 cell line that expresses either the Np63 or the
TAp63 isoform under control of a doxycycline (dox)-inducible promoter. Np63 and TAp63
were subcloned into a lentiviral backbone plasmid downstream of a dox-inducible CMV
promoter. This backbone also contained a cassette for the expression of the reverse Tettransactivator protein, which allows inducible expression of Np63 or TAp63 in the presence of
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tetracycline analogs like dox. This backbone also contained a puromycin resistance gene for
selection of infected cells with puromycin. Virion were produced and cells infected as described
in Materials and Methods, and uninfected cells were removed from the population by selection
with puromycin.
We then confirmed that the infected cell lines produced the phenotypes we desired.
First, we performed a western blot experiment testing for p63 and p53 expression in MCF10a
cells demonstrated that both proteins were expressed in this cell type and served as a positive
control for the p63 antibody (Fig. 3A). We confirmed the construction of the inducible Np63
and TAp63 HCT116 cell lines through western blots an antibody against a common region
present in both p63 isoforms (Figure 3B). In both cases, we did not observe any expression in the
absence of doxycycline, confirming the inducibility of the gene. We next measured expression of
p63 in either control MCF10A or p63shRNA-expressing MCF10A cells after exposures to either
a control (DMSO) or two different p53-activating drugs (Nutlin-3A or etoposide). The rationale
for exposing the cells to the different drugs was demonstrate that p63 and p53 are regulated in
different manners. Expression of p53 increases in response to these drugs (data not shown). As
expected, cells expressing p63shRNA show reduced protein expression of p63 (Fig. 3C).
We then moved forward to test the effect of either removal of p63 (from MCF10A) or
forced expression of p63 (in HCT116) on activity of our different enhancers. Enhancers 220,
231, and 245 were transfected (along with a control vector consitutively expressing Renilla
luciferase) into MCF10a WT, MCF10a p63KD, and HCT116 WT cell lines, and were expressed
in the HCT116 Np63 cell line using 1 µg/µL Doxycycline. A reporter construct lacking an
enhancer was used as a negative control in all Luciferase assays. The Luciferase results were first
normalized to the expression of Renilla, which represents a control to measure transfection
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efficiency across experimental conditions. All of the enhancers were then compared to the
control “no enhancer” value (experimental/control). This allows for the comparison of enhancer
activity and transfection efficiency across conditions and cell types.
The three enhancers we tested appear to have enhancer activity in MCF10A WT cells
(where p63 is expressed natively), as their activity levels are higher than that of the no enhancer
control (Fig. 4). Luciferase assays performed on the same enhancers in a MCF10a p63KD cell
line shows a substantial decrease in their activity levels compared to MCF10a WT cells (Fig. 5).
These differences between control and p63shRNA-expressing cells are statistically significant.
This suggests that p63 is required for full activity of these enhancer elements. To determine if
p63 expression is sufficient to drive this activity, Luciferase assays were performed on HCT116
WT cells (which do not natively express p63). The results show a reduction of enhancer activity
compared to MCFT10A WT cells (Fig. 6). Furthermore, two of the three enhancers showed such
low activity levels that they have the same or worse activity than the no enhancer control. This
suggests that all of the enhancers are more active in MCF10A cells and that two (220 and 231)
have activity in HCT116 cells. To determine if reduction in activity was due to the absence of
p63 in the native cell environment, Luciferase assays were performed on HCT116 inducibleNp63 cells, where expression of the Np63 isoform is forced through the use of a doxycyclineresponsive transcriptional unit. The results show that overexpressing p63 in HCT116 cells was
not sufficient to activate any of the enhancers beyond the level we see in cells lacking p63 (Fig.
7). These data suggest that p63 expression alone is insufficient to drive the activity, but that it is
required for enhancer function in MCF10A cells.
We next wanted to better understand what genes are regulated by p63-bound enhancers.
Enhancers can be great distances from the regulated gene, therefore it is often difficult to
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attribute an enhancers activity to a given gene. To further investigate the activity of these cluster
2 enhancers and the genes that they regulate, we selected an additional ten regions from the
original MPRA experiment that were shown to be enhancers. We designed an experiment using
utilizing CRISPR-dCas9-KRAB to block the activity of a given enhancer element and then
measure the expression of thousands of genes in parallel using RNA-seq. CRISPR-dCas9-KRAB
binds to any region of the genome that we desire and blocks critical transcription factors from
interacting with the enhancer DNA sequences through formation of H3K9me3-enriched
heterochromatin. The guide RNA sequences for dCas9 were designed to target dCas9 KRAB to
the p63 binding sites of the 10 enhancers. We included both a positive control for a known
enhancer at the GDF15 gene and a negative control, which was targeting an enhancer that is
inactive in MCF10A cells (FGF2). Therefore, we could benchmark our results and determine
whether the experiment was performed properly since we had an expectation of the results.
A lentiviral contruct was used to transduce MCF10A cells with a specific gRNA
sequence and dCas9 KRAB, and infected cells were selected using puromycin. Upon
establishment of stably-expressing cell lines, total RNA was isolated and used for polyA+ RNA
selection using polydT-coupled magnetic beads. Barcoded RNA sequencing libraries were
generated from the polyA+RNA for all 12 cell lines. Successful sequencing library generation
was first verified through capilary electrophoresis (Fig.8), in which the presence of DNA
between 200 and 600bp indicate the correct sizes of the RNA sequencing library. These libraries
were then absolutely quantified using known quantities of DNA library using a qPCR-based
approach and pooled together. The library was then sequenced in a 75 cycle/read reaction on an
Illumina NextSeq500 at the Center for Functional Genomics. RNA-expression values
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(Transcripts Per Million, TPM) were generated by aligning the sequenced RNA reads against the
human hg19 RefSeq reference transcriptome using salmon.
The expression level of GDF15, our positive control, was dramatically reduced (≈20
fold) compared to FGF2 targeting (black, control) when the dCas9-KRAB complex was targeted
to it’s known enhancer positive element (Figure 9A). As evidence of specificity, the nearest 7
genes upstream and 7 genes downstream were unaffected by placement of dCas9-KRAB at the
GDF15 enhancer (Figure 7A). We also saw no effect on nearby gene expression when targeting
the FGF2 enhancer, globally (black dots, Figure 9A). When the dCas9-KRAB complex was then
targeted to ten different cluster 2 enhancers, we only found clear evidence of enhancer activity
when targeting dCas9-KRAB to enhancer 197. This led to the downregulation of three nearby
genes, LINC01698, MIR205, and CAMK1G. We confirmed MIR205 expression was reduced
when enhancer 197 was targeted by dCas9-KRAB using RT-qPCR compared to control targeting
of dCas9-KRAB to the inactive FGF2 enhancer. This result is statistically significant (Figure
10). Overall, these data suggest that dCas9-KRAB-targeting to p63 bound enhancers coupled to
RNA-seq can identify gene targets of those enhancers but that not all p63-bound enhancers might
act as enhancers in all contexts.
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Conclusions
A preliminary massively parallel reporter assay (MPRA) revealed a group of enhancers
which only bound to p63 (Fig. 11) and were unable to be bound by the paralog p53. We aimed to
identify whether p63 activity was required for enhancer function and whether p63 binding or
expression alone would be sufficient to activate these enhancers outside of the native cell
context. We then asked whether we could use a targeted enhancer inhibition approach (dCas9KRAB) to identify the gene targets of p63-bound enhancers. We began by asking about the role
of p63 at enhancers by studying three random p63-bound enhancers we chose from our MPRA
screen. We clones the three enhancers from genomic DNA and successfully cloned them into a
Luciferase reporter plasmid. We then used these enhancers to investigate whether p63 can bind
and activate these enhancer regions. These plasmids were then transfected into HCT116 cells,
which natively do not express p63, and demonstrated these enhancers had reduced or no activity.
Expression of both isoforms of p63 in HCT116 cells suggests that p63 expression alone is
insufficient to drive expression of these enhancers.
Our results focus on three different p63-bound enhancers, which our MPRA suggests
might be p63-dependent. In MCF10a WT cells, these DNA sequences seem to have enhancer
activity as suggested by previous assays. In order to determine whether p63 was required, the
MCF10a p63KD cell line was created to modulate levels of p63. Luciferase assays performed on
this cell line shows that the activity of the same three enhancers decreases significantly compared
to the wild-type cell line. These results suggest that p63 is required for the activity of these
enhancers.
To determine whether p63 alone was sufficient to drive the activity of these enhancers,
we performed Luciferase assays on HCT116 WT cells. Compared to MCF10a WT cells, the
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three cluster 2 enhancers all show decreased activity levels in HCT116 WT cells, suggesting
some transcription factors required for MCF10A-level activity are missing. Alternatively, a
repressor protein/proteins might be present in HCT116 that leads to the observed reduction in
activity. Interestingly, two of the enhancers exhibited such low activity levels that they were
equivalent or less than the no enhancer controls, suggesting that enhancer activity is strongly
context and cell type-dependent. Furthermore, when we forced expression of Np63 in HCT116
cells we do not observe an increase enhancer activity. This suggests that p63 alone is not
sufficient to drive the activity of these cluster 2 enhancers.
These data allow us to put forth a potential model for the activity of p63 at enhancers.
p63 involving the differing cellular environments and proteins expressed between the two cell
types. MCF10a cells natively express p63 and are an epithelial cell type, while HCT116 cells do
not express p63 and are a tumor-derived cell lines that is mesenchymal in nature. The most
straightforward model is that p63 activity requires additional factors that are present in MCF10A
cells but absent from HCT116. That is to say, the set of factors and cofactors expressed in
MCF10A allows full enhancer activity. HCT116 colorectal cancer cells are derived from colon.
It is possible that certain transcription factors or cofactors that are required to interact with the
p63 network may be compromised compared to that of MCF10a cells, which are derived from
non-cancerous epithelial cells. Additionally, there may be key epithelial factors present in
MCF10a cells that drive certain enhancers to work better. Further work can be done to examine
the exact cofactors that work with p53- and p63-dependent enhancers in MCF10as, and to
compare the activity of these enhancers in both cell types. One option is to perform saturating
mutagenesis approaches to identify additional DNA sequences within the enhancer regions that
might bind other required transcription factors. Additionally, we could perform DNA
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footprinting experiments to infer the occupancy of different DNA elements within the enhancer.
Finally, and perhaps most importantly, a comprehensive yeast-1-hybrid experiment can be
performed against a bait of the p63-bound enhancer against a prey library of human transcription
factors. This would allow the unambigous identification of the factors binding. This approach is
limited by the difficulty of obtaining a genome-scale transcription factor library and by the nonnative context of the assay (yeast versus intact human cell lines).
We then also sought to investigate the target genes of these p63-dependent enhancers.
This question is perhaps the most difficult in all of transcriptional regulation, due to the highly
contextual nature of enhancers. What we mean by this is that one gene can have many enhancers,
and these enhancers can be redundant or context-dependent. Therefore, if we delete or block a
redundant enhancer, we would be unable to identify the gene target. Further, because enhancers
can be located incredily far from their target gene, proximity-based approaches (such as only
looking at the nearest gene) tend to fail more often than not. We decided to answer this question
in vivo using CRISPR-KRAB dCas9, which rapidly blocks enhancer activity. If we block the
enhancers activity, then we presumably affect the linked gene. In order to measure the gene
without prior knowledge of which gene could be affected by the enhancer, we used a
transcriptome-wide measurement technique called RNAseq. This allowed us to target dCas9KRAB to any enhancer and then measure the effect on the expression of all genes in the genome
in an unbiased fashion.
Ten putative enhancers were chosen at random from our list of regions that were active in
MCF10A cells in the MPRA assay. All of these enhancers showed high p63 occupancy. The
KRAB domain facilitates the assembly of the proteins that generate heterochromatin, which
blocks the activity of the enhancer by preventing the recruitment and binding of critical
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transcription factors and co-factors. Using this approach, we discovered that enhancer 197 likely
controls expression of up to three different genes nearby. Excitingly, one of these genes is
MIR205, a microRNA that appears to be important for epithelial integrity. This is interesting
because regulation of epithelial integrity is the same phenotype shared with p63. Our work
provides a direct link between a master regulator of epithelial biology (p63) and a microRNA
that is required for the same process. There are additional genes regulated by enhancer 197,
including a long noncoding RNA (lncRNA) with as of yet undetermined function. Enhancers
often work in hubs, where one enhancer might regulate expression of multiple promoters.
Therefore, future work could investigate whether this enhancer regulates multiple genes directly
or whether the reduction in expression of three genes is an indirect effect of the reduced
expression of one of those genes. Overall, our work provides evidence for the enhancer function
of this p63-dependent enhancer. Surprisingly, we did not see evidence for gene regulatory
activity of the other p63-dependent enhancers. This can be for a number of biological and
technical reasons. First, p63 has been shown to be repressive, therefore repressing this region
with heterochromatin or with p63 binding might lead to the same functional outcome. RNAseq is
very sensitive, but we did not perform multiple independent biological experiments, which might
help us resolve whether small differences are in fact legitimate. Finally, we know enhancers
oftentimes are redundant and work with other enhancers. In this case, blocking a redundant
enhancer would not provide evidence of regulation unless the other enhancer was blocked.
We propose a model in which p63 works in vivo along with other cofactors in a complex
regulatory network to drive transcription of downstream target genes responsible for epithelial
morphogenesis. Our findings have enabled us to begin to decipher the complex gene regulatory
networks that the p53 family of transcription factors is involved in. By examining the activity of
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p63-bound enhancers in different native cell environments, we begin to understand what defines
an enhancer, what cofactors an enhancer requires, and what transcription factors such as p63 do
when they bind to their enhancer. Our results have also paved the way for distinguishing the
characteristics of p63-bound enhancers from p53 enhancers, which appear to be more active and
functional only after p53 stabilization. Further experiments can then be performed on this
network to investigate other transcription factors that act in combination with these enhancers, as
well as the other target genes of p63-dependent enhancers in addition to MIR205. Ultimately,
understanding how the p63 network regulates gene transcription leads to a better understanding
of the dynamics of these complex regulatory regions.
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Figure 1: Amplifying p63 enhancers out of the genome
PCR reaction run on a 2% agarose gel with a 100bp ladder. Lanes A and B contain reactions to amplify E186,
lanes C and D to amplify E245, lanes E and F to amplify E231, and lanes G and H to amplify E220. Each pair
of lanes contained either 100 or 150 ng of genomic DNA to optimize enhancer amplification.
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Figure 2: Performing Gibson assembly to ligate p63 enhancers with pGL4.24
(A) Gibson primers were first ligated to the four enhancers and then run on a 2% agarose gel with a 100bp ladder.
Lane 1 corresponds to E186, lane 2 to E245, lane 3 to E231, and lane 4 to E220. (B) pGL4.24 was restriction
digested at the HINDIII and KPNI sites, and the cut plasmid was run on a 1% agarose gel with a 1kb ladder.
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Figure 3: p63 is expressed in MCF10a and HCT116 WT cells, and is not
expressed in MCF10a p63KD cells
(A) p63 is expressed in MCF10a cells in the presence of DMSO, 5 µM Nutlin and 100 µM
Etoposide. p53 is expressed in presence of 5µM Nutlin and 100µM Etoposide.
(B) ∆Np63 and TAp63 were expressed in HCT116 WT cells in the presence of 1 µg/mL
Doxycycline.
(C) p63 expression is greatly decreased in MCF10a p63KD cells. This was achieved by
targeting shRNAs to p63 mRNA transcripts to target them for destruction by host machinery.
GAPDH was used as a control in all three experiments
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Figure 4: Cluster 2 enhancers are active in MCF10a cells
(A) Luciferase assay schematic.
(B) Enhancers 220, 231, 245 expressed in MCF10a cells.
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Figure 5: Reduced cluster 2 enhancer activity in MCF10a p63KD cells
compared to MCF10a WT cells
(A) Enhancer 220 expressed in MCF10a p63KD cells vs. MCF10a cells.
(B) Enhancer 231 expressed in MCF10a p63KD cells vs. MCF10a cells.
(C) Enhancer 245 expressed in MCF10a p63KD cells vs. MCF10a cells.
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Figure 6: Cluster 2 enhancers show low activity in HCT116 WT cells
Enhancers 220, 231, 245 expressed in HCT116 WT cells.
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Figure 7: Expressing p63 in a non-native cell context is not sufficient to
increase enhancer activity
Enhancers 220, 231, 245 expressed in HCT116 ΔNp63 cells vs. HCT116 WT cells. ∆Np63
was expressed in HCT116 WT cells in the presence of 1 µg/mL Doxycycline.

26

Figure 8: CRISPR-KRAB dCas9 libraries are of the appropriate size and
composition for sequences
The presence of peaks verifies the correct sizes of the RNA sequencing library. Ten enhancers were
studied along with a positive control, GDF15 and FGF2.
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Figure 9: RNA-seq of KRAB-bound enhancer 197 reveals the
downregulation of 3 downstream genes
(A) The GDF15 enhancer was targeted by dCas9 KRAB as a control.
(B) Targeting dCas9 to enhancer 197 causes the expression of LINC01698, MIR205, and
CAMK1G to decrease.
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Figure 10: qPCR of MIR205 gene
qPCR was performed on the MIR205 gene after dCas9-KRAB
was targeted to enhancer 197.
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